

## **Lehrstuhl für Strahlentherapie**

Intraoperative radiotherapy in elderly patients with breast cancer: long-term follow-up results of the prospective phase II trial TARGIT-E.

**BMC Cancer** 2025; 25(1): ; Impact Factor=n.a.; Impact Factor 2024=3.4; Typ=Journal Article;Clinical Trial, Phase II;Multicenter Study;

Sperk E, Lemanski C, Neumaier C, Lauer J, Siefert V, Völker R, Lindner C, Niehoff P, Tallet AR, Racadot S, Petit A, Pazos M, Le-Blanc Onfroy M, Martin E, Reuter C, Hermann RM, **Pohl F**, Friedrichs K, Würschmidt F, Pigorsch S, Kolberg HC, Graf H, Brunner TB, Malter W, Park-Simon TW, Brucker C, Fleckenstein J, Petersen C, Tuschy B, Wilken EE, Büttner S, Sütterlin M, Flyger H, Wenz F

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) **fehlt**

Feasibility of Adjuvant Radiotherapy or Chemoradiation for Elderly Patients with Squamous Cell Carcinoma of the Head and Neck, and Its Correlation with Different Comorbidity Scores: A Retrospective Cohort Study.

**Cancers (Basel)** 2025; 17(14): ; Impact Factor=n.a.; Impact Factor 2024=4.4; Typ=Journal Article;

**Suess C**, Hipp M, Ettl T, Kuenzel J, Maurer J, Ratzisberger A, **Baier F**, **Steger F**, **Koelbl O**, Hautmann M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) **fehlt**

Benchmarking Large Language Models Against Multidisciplinary Tumor Boards in Urological Oncology: Results from the Blinded, Prospective CONCORDIA Study.

**Eur Urol Oncol** 2025; (): ; Impact Factor=n.a.; Impact Factor 2024=9.3; Typ=Journal Article;

Rinderknecht E, Haas M, Schnabel MJ, Kravchuk AP, Schäfer C, Siepmann S, Mayr R, von Winning D, Grassinger J, Goßler C, **Pohl F**, Siska PJ, Zeman F, Breyer J, Schmelzer A, Gilfrich C, Brookman-May SD, Burger M, May M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) **fehlt**

Competing Risks and Their Impact on Treatment Efficacy Assessment in Fractionated Stereotactic Radiotherapy for Brain Metastases: A Retrospective Study.

**Health Sci Rep** 2025; 8(2): ; Impact Factor=n.a.; Impact Factor 2024=2.1; Typ=Journal Article;

**Gruber I**, **Koelbl O**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) **fehlt**

Dietary habits in relation to outcome and therapy-related toxicity in patients with glioblastoma - a retrospective cohort study.

**J Neurooncol** 2025; 175(1): 345-355; Impact Factor=n.a.; Impact Factor 2024=3.1; Typ=Journal Article;

Haedenkamp TM, Götz L, Ansafi T, Gerken M, Klinkhammer-Schalke M, Fischl A,

Riemenschneider MJ, Maurer J, Proescholdt M, **Kölbl O**, Schmidt NO, Linker R, Bumès E, Hau P  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

Development of a digitalization concept for assessing patient-reported outcomes in the context of a University Cancer Center - a model for use in clinical routine.

**J Patient Rep Outcomes** 2025; 9(1): ; Impact Factor=n.a.; Impact Factor 2024=2.9; Typ=Journal Article;

Saibold A, Koller M, Mueller K, Pukrop T, Rechenmacher M, **Koelbl O**, **Pohl F**, Maurer J  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) **fehlt**

Swallowing and Speaking Evaluation After Resection and Reconstruction Versus Definite Radiochemotherapy for (Sub)total Tongue Cancer.

**Plast Reconstr Surg Glob Open** 2025; 13(3): ; Impact Factor=n.a.; Impact Factor 2024=1.8; Typ=Journal Article;

Ettl T, Meier JK, Kummer P, **Pohl F**, Gerken M, Reichert TE, Bohr C, Vester S  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) **fehlt**

Late Bowel Symptoms in Long-Term Survivors of Prostate Cancer Following Radiotherapy.  
**Prostate** 2025; 85(13): 1181-1188; Impact Factor=n.a.; Impact Factor 2024=2.5; Typ=Journal Article;

**Gruber I**, **Koelbl O**, **Meier MM**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) **fehlt**

Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial.

**Sci Rep** 2025; 15(1): ; Impact Factor=n.a.; Impact Factor 2024=3.9; Typ=Journal Article;Clinical Trial, Phase III;Randomized Controlled Trial;

Gaedcke J, Sahrhage M, Ebeling M, Azizian A, Rühlmann F, Bernhardt M, Grade M, Bechstein WO, Germer CT, Grützmann R, Piso P, Hofheinz RD, Staib L, Beißbarth T, Kosmala R, Fokas E, Rödel C, Ghadimi M, German Rectal Cancer Study Group: R Sauer, W Hohenberger, R Fietkau, G Lahmer, H Golcher, **O. Kölbl**, u. a.

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

Off beam dosimetry for risk group classification for patients with head and neck cancer and CIED.

**Z Med Phys** 2025; (); ; Impact Factor=n.a.; Impact Factor 2024=4.2; Typ=Journal Article;

**Blümlein L**, **Kölbl O**, Ringler R, **Dobler B**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) **fehlt**

Systematizing the risk management process in clinical radiotherapy practice:

Recommendations of the working group on risk management of the DGMP.

**Z Med Phys** 2025; 35(4): 401-407; Impact Factor=n.a.; Impact Factor 2024=4.2; Typ=Journal

Article;

Kornek D, Hoinkis C, Milickovic N, Lange A, Knak A, **März M**, Möller ML, Buchgeister M  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

Zitierfähige Kongressbeiträge:

Multizentrische Analyse von Bestrahlungsplänen bei Salvage-Bestrahlung von Prostatalogen  
Michael Keilholz, Sebastian H. Maier, Jan Peecken, Christian Trapp, Stephan Schönecker, Paul Rogowski, Sarah Frederike Brose, Matthias Zähringer, Claus Belka, **Marius Treutwein**, Leyla Ravasdjani, Florian Putz, **Christoph Süß**, Bülent Polat, Vasiliki Anagnostatou, Nina-Sophie Schmidt-Hegemann "

Kongressbeitrag DEGRO 2025

Strahlenther Onkol (2025) (Suppl 1) 201:S1–S215

Die räumliche Entfernung von Tumor-assoziierten Makrophagen (TAMs) zu Tumorzellen korreliert mit dem pathologischen Komplettansprechen bei Induktionsimmunchemotherapie von lokal fortgeschrittenen Kopf-Hals-Tumoren: Biomarkeranalyse der CheckRad-CD8 Studie"  
Sören Schnellhardt, Markus Eckstein, Thomas Illmer, Gunther Klautke, Simon Laban, Thomas B. Brunner, Balint Tamaskovics, **Christoph Süß**, Maximilian Fleischmann, Jian-Guo Zhou, Benjamin Frey, Wiebke Pirschel, Udo Gaipl, Heinrich Iro, Philipp Schubert, Antoniu-Oreste Gostian, Markus Hecht "Kongressbeitrag DEGRO 2025

Strahlenther Onkol (2025) (Suppl 1) 201:S1–S215

Radio(chemo)therapie in einem jüngeren Patientenkollektiv bei HNSCC – monozentrische Ergebnisse

Leila Erpenstein, Elena Nickel, **Felix Steger, Fabian Baier, Leonhard Guttenberger**, Julia Maurer, Karolina Müller, Julian Künzel, Matthias Hautmann, **Oliver Kölbl, Christoph Süß**

Kongressbeitrag DEGRO 2025

Strahlenther Onkol (2025) (Suppl 1) 201:S1–S215

Hypofractionated radiotherapy of single tumor lesion increases systemic response rate to pembrolizumab in recurrent or metastatic head-and-neck cancer

(R/M-HNSCC): Primary endpoint of the randomized Keynote-717 trial

Schubert P, Tamaskovics B, Haussmann J, Budach W, Illmer T, Radke J, **Koelbl O, Süß C**,

Melchior P, Schnellhardt S, Rödel C, Fleischmann M, Brunner TB, Reinacher-Schick A, Hinke A, Kallies A, Gaipl US, Frey B, Fietkau R, Hecht M

Kongressbeitrag ESMO 2025

PeLeRad: An open-label, randomized multicenter phase II trial of combined pembrolizumab (P) and lenvatinib (L) after definitive chemoradiation of locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in PD-L1 positive patients: results of an interim analysis.

Schnellhardt S, Pirschel W, Linxweiler M, Melchior P, Fleischmann M, **Süß C**, Tamaskovics B ,  
Langer C, Haderlein M, Kahl KH, Eckstein M, Frey B, Gaipl US, Hinke A, Gostian A-O, Freier K,  
Bozzato A, Fietkau R, Hecht M  
Kongressbeitrag ESMO 2025

*Prof. Dr. Oliver Kölbl*